Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (MUK seven)
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2018
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MUK Seven
- 04 Dec 2018 Results evaluating changes in immune cell sub-group composition associated with the addition of cyclophosphamide to pomalidomide in Multiple myeloma patients presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Initial results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 04 Dec 2018 Status changed from recruiting to discontinued.